Glanzmann's thrombasthenia risk factors

Jump to navigation Jump to search

Glanzmann's thrombasthenia

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Glanzmann's thrombasthenia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Glanzmann's thrombasthenia risk factors On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Glanzmann's thrombasthenia risk factors

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Glanzmann's thrombasthenia risk factors

CDC on Glanzmann's thrombasthenia risk factors

Glanzmann's thrombasthenia risk factors in the news

Blogs on Glanzmann's thrombasthenia risk factors

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Glanzmann's thrombasthenia risk factors

Overview

The risk of Glanzmann's thrombathenia in children coming from consanguineous marriage is much higher. [1]

Autoantibodies are another important cause of acquired GT .

Risk Factors

The autoantibodies production can be result of following conditions:

  • Hematologic disorders and malignancies, such as :
  1. acute lymphoblastic leukemia,
  2. non-Hodgkin’s lymphoma
  3. multiple myeloma
  4. hairy cell leukemia
  5. myelodysplastic syndrome
  6. immune thrombocytopenic purpura (ITP)
  • Autoimmune diseases, such as lupus (Blickstein et al)
  • Drugs : anti-thrombotic drugs use , like abciximab, eptifibatide, and tirofiban which all antagonize αIIbβ3
  • platelet transfusions.[6]

References

  1. Schmoldt A, Benthe HF, Haberland G (1975). "Digitoxin metabolism by rat liver microsomes". Biochem Pharmacol. 24 (17): 1639–41. PMC 5922622. PMID 10.1002/ajh.20159 DOI: 10.1002/ajh.20159 Check |pmid= value (help).